Etavopivat
As of the edition of 20 October 2026, Etavopivat is a small molecule: in active development; acts on PKLR.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Small molecule
- Registered trials
- 14, 1 stopped early
- Disease areas
- Blood and lymph; Inherited and neonatal; Digestive system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| PKLR | Pyruvate kinase PKLR | P30613 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 6 | 6 | 0 | 0 |
| Phase 2 | 5 | 2 | 2 | 1 |
| Phase 3 | 3 | 0 | 3 | 0 |
| All trials | 14 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Forma Therapeutics | Lead sponsor of trials | 2018 to now |
| Novo Nordisk | Lead sponsor of trials | 2024 to now |